Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Feature|Articles|February 3, 2026
‘Stay Curious’ Incoming ASCO President Notes Regarding Successes of Career
Author(s)Ariana Pelosci
Fact checked by: Tim Cortese
Deb Schrag, MD, MPH, will assume the role as ASCO president in 2027, and hopes to continue the work of transcending global, political, and geographic barriers in oncology.
Advertisement
Advertisement
Gastrointestinal (GI) cancer, Deb Schrag, MD, MPH, describes as like playing soccer. It’s a team sport, including not just medical oncologists but radiation oncologists, surgeons, and the entire multidisciplinary team. The incoming American Society of Clinical Oncology (ASCO) president for the 2027-28 term began her career at Columbia Presbyterian during the “triple epidemic” of human immunodeficiency virus (HIV), multidrug-resistant tuberculosis, and cocaine. Training during that period changed her point of view and career trajectory.1
Related to this article
Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
Melody Rasouli, MD, MBA, FACOG, explained why male fertility preservation information trails female content online and how cancer centers can fix it.
Advertisement
Advertisement